Tezspire Hits Phase 3 CROSSING Endpoints in Eosinophilic Esophagitis, Teeing Up a Third Indication

Amgen (Nasdaq: AMGN) and AstraZeneca announced positive top-line results from the Phase 3 CROSSING trial of Tezspire (tezepelumab-ekko) in eosinophilic esophagitis (EoE), with the TSLP antibody hitting both co-primary endpoints at Week 24 and carrying the benefit through Week 52. The readout tees up a third epithelial-driven indication for a drug already approved in severe asthma and chronic rhinosinusitis with nasal polyps.

The trial met its two co-primary endpoints. Tezspire produced a statistically significant and clinically meaningful gain in histologic remission, defined as a peak esophageal eosinophil count of six or fewer per high-power field, and a meaningful improvement in dysphagia measured on the Dysphagia Symptom Questionnaire. Both benefits held through Week 52. The study randomized 368 patients 1:1:1 to a low or high dose of Tezspire or placebo.

EoE is a chronic inflammatory disorder of the esophagus that affects more than 470,000 people in the U.S., with prevalence up five-fold since 2009. The inflammation narrows the esophagus and makes swallowing difficult, raising the risk of food impaction. Nearly half of patients, including adolescents, do not get adequate control from the standard first-line options of dietary elimination, swallowed topical corticosteroids, and proton pump inhibitors.

The mechanism is the point. Tezspire blocks thymic stromal lymphopoietin (TSLP), an epithelial cytokine that sits at the top of multiple inflammatory cascades. That upstream position is why the same antibody keeps showing activity across what Amgen calls epithelial-driven diseases. Tezspire won its first approval in severe asthma in 2021 and added CRSwNP last year. EoE would be the third, and Amgen is also running the drug in COPD across the COURSE, JOURNEY, and EMBARK trials.

The commercial setup is a co-development with AstraZeneca. The two split global costs and profits evenly, AstraZeneca leads development, and Amgen books U.S. sales. For Amgen, that makes Tezspire a rare large-cap growth driver, and EoE extends the runway beyond the crowded asthma market.

The competition is real. Dupixent (dupilumab) is already approved for EoE and anchors Sanofi’s immunology franchise, so Tezspire would enter as a second biologic, differentiated by its every-four-weeks dosing and its TSLP-first mechanism rather than Dupixent’s IL-4/IL-13 blockade.

Amgen shares barely budged, trading around $440, flat from Wednesday’s $440.34 close. The readout was largely expected after the WAYPOINT CRSwNP data proved the drug’s epithelial-driven thesis. What to watch next: the full Week 52 dataset at a medical meeting, and whether Amgen and AstraZeneca file for the EoE label, which would make Tezspire a three-indication franchise.

What It Means for the Trade

A flat stock on a clean Phase 3 win tells you the market had this readout mostly priced — the WAYPOINT CRSwNP data had already validated the epithelial-driven platform thesis, and CROSSING was the confirmation leg. That does not make the result unimportant; it makes the mispricing opportunity smaller and shifts the value question to label economics. EoE is a market where Dupixent demonstrated that a biologic can build a meaningful franchise: Sanofi and Regeneron’s drug won its EoE approval and turned it into a growth indication, and that precedent is what makes CROSSING worth more than a flat stock reaction implies. Tezspire entering EoE as the second biologic is not a problem — second-to-market biologics in immunology routinely take durable minority share on mechanism and dosing differentiation, and Tezspire has both.

The dosing point is the commercial crux. Dupixent is dosed every two weeks for EoE; Tezspire is a every-four-weeks drug. In a chronic disease diagnosed increasingly in adolescents and young adults, halving the infusion or injection burden is a real differentiator in patient preference and in clinic throughput. The TSLP-first mechanism is the second lever: Tezspire blocks upstream of the IL-4/IL-13 axis Dupixent targets, which in principle covers type 2 and non-type 2 inflammatory drivers alike — and EoE is a disease where a meaningful share of patients are not clean type 2 responders. The cross-trial caution applies: CROSSING and Dupixent’s EoE program were separate trials with different designs, and the dysphagia instruments differ enough that head-to-head inference is approximate until the full datasets sit side by side.

Franchise and Pipeline Context

The franchise math for Amgen is the quiet part of this story. Tezspire is co-developed with AstraZeneca — even cost/profit split, AstraZeneca leads development, Amgen books U.S. sales — and it is one of the few genuine growth assets in a portfolio that skews toward mature franchises and pipeline binaries. A third indication compounds the value: each label adds prescriber familiarity that lifts utilization across all three, and the COPD program (COURSE, JOURNEY, EMBARK) is the real prize still in the deck, because COPD is a far larger market than asthma, CRSwNP, and EoE combined and has almost no approved biologic options. The EoE label makes the COPD filings easier to underwrite: three straight Phase 3 wins in epithelial diseases is a pattern, not a coincidence, and it raises the prior on the COPD readouts.

For AstraZeneca the readout is similar but smaller in portfolio terms — another epithelial indication for a respiratory-heavy franchise. The two companies’ incentives are aligned here, which is why the development cadence has been steady: one indication per year since 2024 is disciplined pipeline execution on a single asset, something both partners’ shareholders should want more of.

Risks and What Could Go Wrong

1. Dupixent’s incumbency in EoE is not a small obstacle: it has the KOL relationships, the payer coverage precedents, and the pediatric label position. Tezspire’s filing will need to win share on differentiation, not on clinical superiority the data does not claim.
2. The Week 52 durability cut: histologic remission holding through 52 weeks is stated, but the depth of the Week 24-to-52 data — relapse rates, steroid use, food-impaction events — will determine whether the label claims are maintenance-grade or induction-grade.
3. The COPD trials remain the binary that can re-rate the franchise in either direction; nothing in CROSSING de-risks them, and a TSLP miss in COPD would cap the whole epithelial-driven narrative.
4. Pricing: entering an established biologic market second means benchmarking against Dupixent’s price, which compresses the margin of upside from any EoE revenue modeling.

None of this is a standalone reason to buy AMGN — the stock trades on cholesterol franchise anxiety and obesity pipeline news, not on a third Tezspire label. But as a franchise-building block it is one of the cleaner wins in the large-cap immunology space this year, and the COPD readouts are the events that will tell you whether the market re-rates it.

Source: Amgen press release, August 27, 2026